Extensive research has shown that the myelin sheath found on the axons of motor neurons is breaking down. Scientists are investigating several different approaches to slow, stop and reverse this loss in ALS patients.
This protein biologic is designed to be highly specific to the cell surface receptor it binds to. Our team is working quickly to complete survival efficacy experiments on this approach to determine whether or not it merits clinical development.
Topics in the Pipeline
Register now for our upcoming webinar on May 10th at 6pm: FDA approves Radicava - What do we need to know?
#WHATWOULDYOUGIVE to #ENDALS?
For ALS Awareness Month, join our #InThreeWords campaign on social media.
Please give to ALS TDI to help us get promising treatments out of our lab and into people living with ALS.
November 28 is
You've taken the challenge, now help
move promising treatments out of our
lab and into people living with ALS.